Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Sep;18(9):1160-1170.
doi: 10.6004/jnccn.2020.0043.

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

Robert J Motzer  1 , Eric Jonasch  2 , Shawna Boyle  3 , Maria I Carlo  1 , Brandon Manley  4 , Neeraj Agarwal  5 , Ajjai Alva  6 , Katy Beckermann  7 , Toni K Choueiri  8 , Brian A Costello  9 , Ithaar H Derweesh  10 , Arpita Desai  11 , Saby George  12 , John L Gore  13 , Naomi Haas  14 , Steven L Hancock  15 , Christos Kyriakopoulos  16 , Elaine T Lam  17 , Clayton Lau  18 , Bryan Lewis  19 , David C Madoff  20 , Brittany McCreery  13 , M Dror Michaelson  21 , Amir Mortazavi  22 , Lakshminarayanan Nandagopal  23 , Phillip M Pierorazio  24 , Elizabeth R Plimack  25 , Lee Ponsky  26 , Sundhar Ramalingam  27 , Brian Shuch  28 , Zachary L Smith  29 , Bradley Somer  30 , Jeffrey Sosman  31 , Mary A Dwyer  32 , Angela D Motter  32
Affiliations
Practice Guideline

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

Robert J Motzer et al. J Natl Compr Canc Netw. 2020 Sep.

Abstract

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for genetic testing, surveillance, and/or treatment options for patients who are suspected or confirmed to have one of these syndromes.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30. - PubMed
    1. Moch H, Gasser T, Amin MB, et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000; 89:604–614. - PubMed
    1. Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010;183:1309–1315. - PubMed
    1. Lipworth L, Morgans AK, Edwards TL, et al. Renal cell cancer histological subtype distribution differs by race and sex. BJU Int 2016;117:260–265. - PubMed
    1. Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol 2018;36:1891–1898. - PMC - PubMed

Publication types

MeSH terms